Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
In this meta-analysis, we aimed to estimate and compare the efficacy of add-on treatment of antidepressants with esketamine nasal spray and second-generation antipsychotics in patients with nonpsychotic major depressive disorder and inadequate response to antidepressants. Searching for acute-phase, double-blind, placebo-controlled, randomized trials, we found 22 second-generation antipsychotic (n = 8363) and 3 intranasal esketamine (n = 641) studies. Mean change in the Montgomery Åsberg Depression Rating Scale total score served as outcome. We determined a higher mean difference (vs placebo) for the pooled esketamine nasal spray trials (mean difference = 4.09, 95% confidence interval: 2.01 to 6.17) than for the pooled second-generation antipsychotic augmentation trials (mean difference = 2.05, 95% confidence interval: 1.51 to 2.59). Thus, the effect size for intranasal esketamine was nearly twice as high as those for the second-generation antipsychotics. This indicates high efficacy of add-on esketamine nasal spray in treatment-resistant major depressive disorder compared with other well-established, evidence-based pharmacological options such as augmentation with second-generation antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta- analytic data also indicate that glutamatergic treatment strategies may be superior to antipsychotic agents in adults with TRD 200,201 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [200]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Mean change (from study baseline to endpoint) in the Montgomery Åsberg Depression Rating Scale (MADRS) total score (Montgomery and Asberg, 1979) served as outcome.”
MethodCumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · cited 2×
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
BackgroundPapakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382 · cited 2×
“This increased response preferentially affects placebo groups rather than active treatment groups, resulting in a lower verum-placebo separation at study endpoint (Papakostas and Fava, 2009; Sinyor et al., 2010).”
BackgroundPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284 · cited 1×
“…as evidence-based strategy in resistant MDD (Souery et al., 2011; Bauer et al., 2017; Dold and Kasper, 2017; Bartova et al., 2019), there is some evidence that at least some patients appear to benefit even from a within-class switch of the antidepressant compound (Papakostas et al., 2008).”
BackgroundInternational trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuoliené, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 282
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268 · cited 2×
“…be considered that investigations focusing on the mechanisms of placebo response in clinical trials revealed an association between high likelihood for receiving active treatment and increased response, mainly due to enhanced hope induction (Rutherford and Roose, 2013; Kasper and Dold, 2015).”
BackgroundZhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197 · cited 1×
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
BackgroundSinyor, M., Levitt, A. J., Cheung, A. H., Schaffer, A., Kiss, A., Dowlati, Y., & Lanctôt, K. L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04516blu · Cited by 189 · cited 1×
“This increased response preferentially affects placebo groups rather than active treatment groups, resulting in a lower verum-placebo separation at study endpoint (Papakostas and Fava, 2009; Sinyor et al., 2010).”
BackgroundPharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
Self-citationMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121 · cited 1×
“Moreover, the mean MADRS difference of intranasal esketamine is much higher than the 2-point difference suggested by Montgomery and Moller (2009) to consider an antidepressant-placebo separation to be clinically meaningful.”
BackgroundSouery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182228619 · Cited by 119 · cited 1×
“Even if a switch to another, new antidepressant drug after insufficient response to the currently administered antidepressant cannot generally be regarded as evidence-based strategy in resistant MDD (Souery et al., 2011; Bauer et al., 2017; Dold and Kasper, 2017; Bartova et al., 2019), there is some evidence that at l…”
BackgroundSelf-citationEvidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118 · cited 2×
“Even if a switch to another, new antidepressant drug after insufficient response to the currently administered antidepressant cannot generally be regarded as evidence-based strategy in resistant MDD (Souery et al., 2011; Bauer et al., 2017; Dold and Kasper, 2017; Bartova et al., 2019), there is some evidence that at l…”
BackgroundSelf-citationAdministration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110 · cited 1×
“With esketamine, a new pharmacological compound characterized by a glutamatergic mechanism of action became most recently available to treat resistant MDD (Kraus et al., 2017).”
BackgroundSelf-citationDold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66 · cited 1×
“Accordingly, pharmacoepidemiological surveys consistently revealed a substantial increase of SGA prescriptions in MDD over the last decades (Konstantinidis et al., 2012; Dold et al., 2016; Halfdanarson et al., 2017).”
BackgroundSelf-citationKonstantinidis, A., Papageorgiou, K., Grohmann, R., Horvath, A., Engel, R., & Kasper, S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000745 · Cited by 37 · cited 1×
“Accordingly, pharmacoepidemiological surveys consistently revealed a substantial increase of SGA prescriptions in MDD over the last decades (Konstantinidis et al., 2012; Dold et al., 2016; Halfdanarson et al., 2017).”
BackgroundSelf-citationRational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29 · cited 2×
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
BackgroundDold, M., Bartova, L., Kautzky, A., Serretti, A., Porcelli, S., Souery, D., Mendlewicz, J., Montgomery, S., Zohar, J., & Kasper, S. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.10.003 · Cited by 21 · cited 1×
“In this context, it should be considered that SGAs are especially recommended if MDD is accompanied by psychotic symptoms (Bauer et al., 2017; Dold et al., 2018).”
BackgroundSelf-citationFactors contributing to the increasing placebo response in antidepressant trials
Kasper, S. F., & Dold, M. (2015) · World Psychiatry · doi:10.1002/wps.20245 · Cited by 17 · cited 2×
“…be considered that investigations focusing on the mechanisms of placebo response in clinical trials revealed an association between high likelihood for receiving active treatment and increased response, mainly due to enhanced hope induction (Rutherford and Roose, 2013; Kasper and Dold, 2015).”
BackgroundSelf-citation
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationNovel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Self-citationEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Metadata
- Authors
- Dold, M., Bartova, L., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-22
- Volume
- 23
- Issue
- 7
- Pages
- 440-445
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7387762
- OpenAlex
- W3036507891
- Cited by
- 34
- References
- 23
- Citations by year
- 2026: 4 · 2025: 7 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, intranasal esketamine, treatment-resistant depression, major depressive disorder, atypical antipsychotics, antidepressant augmentation, adjunctive therapy, treatment response
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Major Depressive Disorder, Drug Therapy, Combination, Humans, Ketamine, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.